Articles

O.07 Mutational Landscaping of Liver Metastases with Desmoplastic and Replacement Growth Patterns

BJMO - 2017, issue 3, february 2017

P-J. Van Dam MD, B. Galjart , P. De Paepe MD, PhD, T. Feryn , V. Duwel , L. Dirix MD, P. Vermeulen , S. Van Laere PhD

Read more

O.08 Evaluation of HER2 expression and amplification in CTCs using CellSearch immunofluorescence and FISH

BJMO - 2017, issue 3, february 2017

A. Brouwer , P-J. Van Dam MD, E. Sluydts , M. Peeters MD, PhD, P. Vermeulen , S. Van Laere PhD, L. Dirix MD

Read more

Transforming growth factor β: friend or foe in disguise?

BJMO - volume 6, issue 6, december 2012

M. Marsan , P. Neven MD, PhD, P. Vermeulen , L. Dirix MD, S. Van Laere PhD

TGF-β is a major regulator and driver of many biological processes, but its main function is inhibition of cell cycle progression and apoptosis, thus establishing a tumour-protective effect in early stages of malignant transformation. However, mutational alterations can occur at different levels of the TGF-β signaling cascade. These mutations, combined with the significant influence of the tumour microenvironment on this cascade, can cause a functional shift of TGF-β from being a tumour suppressor to becoming a tumour promoter in more advanced cancers. In most tumours this will ultimately contribute to the formation of metastatic laesions. In the clinical setting of breast cancer, TGF-β plays a significant role in the acquisition of endocrine resistance. Thus, therapeutic intervention of TGF-β signaling might deliver significant benefits in the treatment of cancer. (BELG J MED ONCOL 2012;6:188–193)

Read more
X